Home » Regeneron Lands $450 Million Federal Contract for COVID-19 Antibody Cocktail
Regeneron Lands $450 Million Federal Contract for COVID-19 Antibody Cocktail
Regeneron Pharmaceuticals has been granted a $450 million contract with HHS and the Department of Defense to manufacture and supply its antibody cocktail REGN-COV2 for the treatment of COVID-19 patients.
The contract is the first granted under the Trump administration’s Operation Warp Speed to support development and manufacturing of a potential COVID-19 therapeutic.
The dual antibody cocktail entered a phase 3 trial this week to assess its ability to prevent infection among people exposed to coronavirus patients.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May